Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 3, 2022 7:30 AM EDTARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022
ARCALYST full-year 2022 net revenue expected to be $115 - $130 million
 Upfront and near-term proceeds of $100 million expected from vixarelimab global license agreement
Cash reserves after the close of the vixarelimab global license agreement expected to fund operations into at least 2025 Conference call and webcast scheduled for 8:30 am ETÂ todayÂ
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) --... More
